Table III.
Distribution of MMP3 and MMP9 genotypes and alleles frequency in patients with BC and healthy females.
| Genes | Genotype | Patients, n (%) (n=162) | Controls, n (%) (n=146) | χ2 | P-value | OR | 95% CI |
|---|---|---|---|---|---|---|---|
| MMP3 | 6A/6A | 110 (67.901) | 126 (86.301) | 14.516 | 0.003a | Reference (1) | |
| 5A/6A | 40 (24.691) | 18 (12.321) | 7.678 | 0.006a | 2.545a | 1.379-4.695 | |
| 5A/5A | 12 (7.407) | 2 (0.69) | 6.452 | 0.011a | 5.760 | 1.267-26.187 | |
| Alleles | 5A | 64 (19.753) | 22 (7.534) | 19.089 | <0.001a | 3.021a | 1.808-5.048 |
| 6A | 260 (80.246) | 270 (92.465) | 0.331 | 0.198-0.553 | |||
| MMP9 | CC | 137 (84.567) | 130 (89.042) | 1.332 | 0.249 | Reference (1) | |
| CT | 25 (15.432) | 16 (10.958) | 1.483 | 0.7573-2.9028 | |||
| TT | 0 (0) | 0 (0) | |||||
| Alleles | C | 299 (92.284) | 276 (94.521) | 1.237 | 0.266 | 0.693 | 0.363-1.326 |
| T | 25 (7.716) | 16 (5.479) | 1.442 | 0.754-2.759 |
aStatistically significant (P<0.05). A χ2 test was used to compare the genotype distribution among subjects studied. BC, breast cancer; MMP, matrix metalloproteinase; OR, odds ratio.